Common Cholesterol Medication May Have Fewer Side Effects Than Labels Suggest

Statins are among the most commonly prescribed medications worldwide, taken by millions of adults to lower high cholesterol and reduce the risk of heart attack and stroke. Yet roughly half of patients prescribed them stop within the first year, often citing concerns about side effects. A major new study published in The Lancet suggests that many of those concerns may not be warranted.

Statins work by lowering levels of low-density lipoprotein (LDL) cholesterol, commonly known as 'bad' cholesterol, in the blood. Elevated LDL cholesterol is a well-established risk factor for conditions such as angina, coronary heart disease, and stroke. Because statins are typically prescribed as a long-term treatment, concerns about side effects have always carried particular weight for patients.

What the research found

The study, led by researchers from the University of Oxford's Department of Population Health, analysed data from nearly two dozen large-scale randomised trials involving more than 120,000 participants. The authors describe it as the most comprehensive assessment of statin side effects conducted to date.

The analysis found that, beyond the already established risks of muscle pain and, in some cases, diabetes, only four additional side effects listed on current labels are supported by evidence. These are minor changes in liver enzyme readings, small abnormalities in liver function, changes in urine, and tissue swelling.

Researchers described the risks associated with all four as very small. It is also worth noting that the majority of diabetes cases observed in trials occurred in patients who already had markers close to the diagnostic threshold before treatment began.

Many other side effects currently listed on packaging, including memory problems, depression, sleep disturbances, sexual dysfunction, and nerve-related tingling in the hands and feet, were found not to be caused by statins, even though patients sometimes experience these conditions while taking the medication. The researchers attribute this to the nature of long-term treatment: statins are most commonly prescribed to older adults, a group in whom many of these conditions develop independently with age. When a symptom appears during a course of medication, it is natural to connect the two, but the data from this analysis do not support a causal link. The researchers conclude that the benefits of statin therapy significantly outweigh the risks in the populations for whom the drug is indicated.

The consequences of overcautious labelling

The study is driven by a practical concern. Approximately half of patients prescribed statins stop taking them within the first year, a rate researchers consider clinically significant given the consequences of untreated high cholesterol. The authors argue that inaccurate or overstated warnings on patient information leaflets may be contributing to this pattern, leading people to discontinue a treatment that could otherwise protect them from life-threatening cardiovascular events.

Current labelling requirements, set by regulators including the European Medicines Agency and national authorities, reflect a precautionary framework in which adverse reactions, once added to a label, are rarely removed. Some external researchers have noted that although the Oxford study is an important step, further evidence will be needed before a full regulatory revision can be considered.

What this means for patients

For anyone currently taking statins or who has been advised to consider them, the key message from this research is that many of the concerns associated with these medications are not supported by clinical data. Stopping statin therapy without medical guidance carries its own risks, as cholesterol levels are likely to return to their previous levels once treatment is discontinued.

If you have questions about statins, are experiencing symptoms you believe may be related to your medication, or have been hesitant to start a prescribed course of treatment, the appropriate step is to speak with your doctor. Decisions about long-term medication should always be made in consultation with a clinician who can assess your individual risk profile and medical history.

Source: Financial Times, «Labels on statins overstate side effects, study finds», Aanu Adeoye